Neuroendocrine Tumor

P=N/A, N=117, Completed, Novartis Pharmaceuticals

Cyfra 21-1 demonstrates potential as a valuable serum biomarker for both the diagnosis and prognosis of thymic tumors. Particular attention should be directed toward the diagnosis, treatment strategy, and postoperative surveillance of patients presenting with elevated Cyfra 21-1 levels.

Treatment with long-acting somatostatin analogs led to rapid symptom improvement, and the patient was ultimately cured following surgical resection of the hepatic tumor. Although rare, primary hepatic gastrinomas should be considered in the differential diagnosis of functional NETs with isolated liver lesions.

This review proposes an MRI-first, tiered imaging strategy and a pragmatic approach to tracer selection from the available armamentarium ([11C]methionine, [68 Ga]SSTR ligands, [68 Ga]PentixaFor, [18F]FET and [18F]FDG). We emphasise how to optimise PET acquisition and reporting, and how to integrate imaging with endocrine phenotype, treatment history and surgical/radiosurgical planning to maximise clinical impact while safeguarding pituitary function.

Importantly, while sT-Ag alone induces partial MCC-associated gene expression, suppression of p53 is required for sT-Ag to induce neuroendocrine lineage transdifferentiation in the hair follicle. Cumulatively, these studies enhance our knowledge of MCC biology and establish a de novo MCC tumorigenesis model in a tractable immunocompetent system that will be invaluable for further advancements in the field.

SF3B1 somatic mutation status in lactotroph tumours-as assessed by digital PCR technology-is associated with a younger age at diagnosis and larger tumour diameter. However, in our cohort it does not appear to associate with histological features, higher recurrence, treatment resistance, tumour invasiveness, or long-term outcomes in our multi-centric cohort.

We present a case of a 68-year-old woman with metastatic functional PanNET (VIPoma) who developed a treatment-associated hypermutated, microsatellite instability-high (MSIhigh) phenotype following capecitabine-temozolomide (CAPTEM) therapy. Treatment with pembrolizumab resulted in a robust clinical, biochemical, and radiographic response. This case highlights dynamic genomic evolution in PanNETs and underscores the importance of serial molecular profiling in guiding therapeutic decisions.

P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

This integrative study reveals that MICA/MICB downregulation and SUSD1 upregulation converge to suppress NKG2D-mediated antitumor immunity in cervical cancer, creating an immune-cold TME that limits current immunotherapy and radionuclide targeting efficacy. The NKG2D ligand expression landscape mapped here delineates a precision RNT strategy: scRNA-seq-guided patient stratification, radiolabeled anti-MICA/MICB nanobody theranostic imaging to confirm surface target density, and combination radioimmunotherapy integrating MICA/MICB re-expression induction with targeted radionuclide delivery to selectively irradiate the NKG2D-ligand-negative tumor cell population.

P3, N=69, Completed, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Completed

This case highlights an unusual presentation of a rare malignancy in a duodenal neuroendocrine tumor identified during evaluation of iron deficiency anemia. It emphasizes the importance of comprehensive endoscopic assessment and targeted biopsy in patients with unexplained anemia, including consideration of uncommon gastrointestinal neoplasms.

Samples remained stable at ambient temperature for up to 10 days and at -80 °C for up to 5 years, with no impact from shipping conditions. NETest2.0® demonstrates high analytical sensitivity, precision, and robustness, supporting its validity for clinical application in NET management.